Striatal NTS 1, dopamine D 2 and NMDA receptor regulation of pallidal GABA and glutamate release - a dual-probe microdialysis study in the intranigral 6-hydroxydopamine unilaterally lesioned rat

European Journal of Neuroscience

Volumn 35, Issue 2, 2012, Pages 207-220

  Ferraro, Luca ^a   O'Connor, William T ^b   Beggiato, Sarah ^a   Tomasini, Maria C ^a   Fuxe, Kjell ^c   Tanganelli, Sergio ^a   Antonelli, Tiziana ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF LIMERICK   (Ireland)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Basal ganglia; Dual probe microdialysis; Indirect pathway; Neurotensin receptor antagonists; Parkinson's disease

Indexed keywords

4 AMINOBUTYRIC ACID; DOPAMINE 2 RECEPTOR; ETICLOPRIDE; GLUTAMIC ACID; MECLINERTANT; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTENSIN; NEUROTENSIN 1 RECEPTOR; NEUROTENSIN RECEPTOR; OXIDOPAMINE; QUINPIROLE; UNCLASSIFIED DRUG;

AKINESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN DAMAGE; BRAIN LEVEL; CONTROLLED STUDY; CORPUS STRIATUM; DIALYSATE LEVEL; DOPAMINERGIC SYSTEM; GABAERGIC TRANSMISSION; GLOBUS PALLIDUS; MALE; MICRODIALYSIS; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RAT;

ADRENERGIC AGENTS; ANIMALS; CORPUS STRIATUM; GAMMA-AMINOBUTYRIC ACID; GLOBUS PALLIDUS; GLUTAMIC ACID; MALE; MICRODIALYSIS; NEURAL PATHWAYS; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, NEUROTENSIN; SYNAPTIC TRANSMISSION;

EID: 84855923294     PISSN: 0953816X     EISSN: 14609568     Source Type: Journal    
DOI: 10.1111/j.1460-9568.2011.07949.x     Document Type: Article

References (95)

1. Abarca, J. & Bustos, G. (1999) Differential regulation of glutamate, aspartate and gamma-amino-butyrate release by N-methyl-d-aspartate receptors in rat striatum after partial and extensive lesions to the nigro-striatal dopamine pathway. Neurochem. Int., 35, 19-33.
2. 3H]N-propylnorapomorphine binding sites. Acta Physiol. Scand., 117, 299-301.
3. Albin, R.L., Young, A.B. & Penney, J.B. (1989) The functional anatomy of basal ganglia disorders. Trends Neurosci., 12, 366-375.
4. Alexander, G.E. & Crutcher, M.D. (1990) Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci., 13, 266-271.
5. Alexander, M.J. & Leeman, S.E. (1998) Widespread expression in adult rat forebrain of mRNA encoding high-affinity neurotensin receptor. J. Comp. Neurol., 28, 475-500.
6. Antonelli, T., Tomasini, M.C., Finetti, S., Giardino, L., Calzà, L., Fuxe, K., Soubrié, P., Tanganelli, S. & Ferraro, L. (2002) Neurotensin enhances glutamate excitotoxicity in mesencephalic neurons. J. Neurosci. Res., 70, 766-773.
7. Antonelli, T., Ferraro, L., Fuxe, K., Finetti, S., Fournier, J., Tanganelli, S., De Mattei, M. & Tomasini, M.C. (2004) Neurotensin enhances endogenous extracellular glutamate levels in primary cultures of rat cortical neurons. Involvement of neurotensin receptor in NMDA induced excitotoxicity. Cereb. Cortex, 14, 466-473.
8. Antonelli, T., Fuxe, K., Agnati, L., Mazzoni, E., Tanganelli, S., Tomasini, M.C. & Ferraro, L. (2006) Experimental studies and theoretical aspects on A2A/D2 receptor interactions in a model of Parkinson's disease. Relevance for L-dopa induced dyskinesias. J. Neurol. Sci., 248, 16-22.
9. Antonelli, T., Fuxe, K., Tomasini, M.C., Mazzoni, E., Agnati, L.F., Tanganelli, S. & Ferraro, L. (2007a) Neurotensin receptor mechanisms and its modulation of glutamate transmission in the brain. Relevance for neurodegenerative diseases and their treatment. Prog. Neurobiol., 83, 92-109.
10. Antonelli, T., Tomasini, M.C., Fuxe, K., Agnati, L.F., Tanganelli, S. & Ferraro, L. (2007b) Receptor-receptor interactions as studied with microdialysis. Focus on NTR/D2 interactions in the basal ganglia. J. Neural. Transm., 114, 105-113.
11. Antonelli, T., Tomasini, M.C., Fournier, J., Mazza, R., Tanganelli, S., Pirondi, S., Fuxe, K. & Ferraro, L. (2008) Neurotensin receptor involvement in the rise of extracellular glutamate levels and apoptotic nerve cell death in primary cortical cultures after oxygen and glucose deprivation. Cereb. Cortex, 18, 1748-1757.
12. Binder, E.B., Kinkead, B., Owens, M.J. & Nemeroff, C.B. (2001) Neurotensin and dopamine interactions. Pharmacol. Rev., 53, 453-486.
13. Binder, E.B., Kinkead, B., Owens, M.J. & Nemeroff, C.B. (2004) Neurotensin receptor antagonist SR 142948A alters Fos expression and extrapyramidal side effect profile of typical and atypical antipsychotic drugs. Neuropsychopharmacology, 29, 2200-2207.
14. Boudin, H., Pélaprat, D., Rostène, W. & Beaudet, A. (1996) Cellular distribution of neurotensin receptors in rat brain: immunohistochemical study using an antipeptide antibody against the cloned high affinity receptor. J. Comp. Neurol., 373, 76-89.
15. Boudin, H., Pélaprat, D., Rostène, W., Pickel, V.M. & Beaudet, A. (1998) Correlative ultrastructural distribution of neurotensin receptor proteins and binding sites in the rat substantia nigra. J. Neurosci., 18, 8473-8484.
16. Boules, M., Warrington, L., Fauq, A., McCormick, D. & Richelson, E. (2001) Antiparkinson-like effects of a novel neurotensin analog in unilaterally 6-hydroxydopamine lesioned rats. Eur. J. Pharmacol., 428, 227-233.
17. Boules, M., Fredrickson, P. & Richelson, E. (2006) Bioactive analogs of neurotensin: focus on CNS effects. Peptides, 27, 2523-2533.
18. Brog, J.S. & Zahm, D.S. (1996) Morphologically distinct subpopulations of neurotensin-immunoreactive striatal neurons observed in rat following dopamine depletions and D2 receptor blockade project to the globus pallidus. Neuroscience, 74, 805-812.
19. Brouard, A., Pelaprat, D., Dana, C., Vial, M., Lhiaubet, A.M. & Rostène, W. (1992) Mesencephalic dopaminergic neurons in primary cultures express functional neurotensin receptors. J. Neurosci., 12, 1409-1415.
20. Cadet, J.L. & Zhu, S.M. (1992) The intrastriatal 6-hydroxydopamine model of hemiparkinsonism: quantitative receptor autoradiographic evidence of correlation between circling behavior and presynaptic as well as postsynaptic nigrostriatal markers in the rat. Brain Res., 595, 316-326.
21. Carraway, R. & Leeman, S.E. (1973) The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J. Biol. Chem., 248, 6854-6861.
22. Chalon, P., Vita, N., Kaghad, M., Guillemot, M., Bonnin, J., Delpech, B., Le Fur, G., Ferrara, P. & Caput, D. (1996) Molecular cloning of a levocabastine-sensitive neurotensin binding site. FEBS Lett., 386, 91-94.
23. Chevalier, G. & Deniau, J.M. (1990) Disinhibition as a basic process in the expression of striatal functions. Trends Neurosci., 13, 277-280.
24. Díaz-Cabiale, Z., Fuxe, K., Narváez, J.A., Finetti, S., Antonelli, T., Tanganelli, S. & Ferraro, L. (2002) Neurotensin-induced modulation of dopamine D2 receptors and their function in rat striatum: counteraction by a NTR1-like receptor antagonist. Neuroreport, 13, 763-766.
25. Dobner, P.R., Fadel, J., Deitemeyer, N., Carraway, R.E. & Deutch, A.Y. (2001) Neurotensin-deficient mice show altered responses to antipsychotic drugs. Proc. Natl. Acad. Sci. USA, 98, 8048-8053.
26. Dobner, P.R., Deutch, A.Y. & Fadel, J. (2003) Neurotensin: dual roles in psychostimulant and antipsychotic drug responses. Life Sci., 73, 801-811.
27. Drew, K.L., O'Connor, W.T., Kehr, J. & Ungerstedt, U. (1990) Regional specific effects of clozapine and haloperidol on GABA and dopamine release in rat basal ganglia. Eur. J. Pharmacol., 187, 385-397.
28. Dunah, A.W., Wang, Y., Yasuda, R.P., Kameyama, K., Huganir, R.L., Wolfe, B.B. & Standaert, D.G. (2000) Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-d-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease. Mol. Pharmacol., 57, 342-352.
29. Engber, T.M., Boldry, R.C., Kuo, S. & Chase, T.N. (1992) Dopaminergic modulation of striatal neuropeptides: differential effects of D1 and D2 receptor stimulation on somatostatin, neuropeptide Y, neurotensin, dynorphin and enkephalin. Brain Res., 581, 261-268.
30. 2 receptors in rat striatal membranes following treatment with toluene. Acta Physiol. Scand., 135, 442-448.
31. Fadel, J., Dobner, P.R. & Deutch, A.Y. (2001) The neurotensin antagonist SR 48692 attenuates haloperidol-induced striatal Fos expression in the rat. Neurosci. Lett., 303, 17-20.
32. Fantin, M., Marti, M., Auberson, Y.P. & Morari, M. (2007) NR2A and NR2B subunit containing NMDA receptors differentially regulate striatal output pathways. J. Neurochem., 103, 2200-2211.
33. Fassio, A., Evans, G., Grisshammer, R., Bolam, J.P., Mimmack, M. & Emson, P.C. (2000) Distribution of the neurotensin receptor NTS1 in the rat CNS studied using an amino-terminal directed antibody. Neuropharmacology, 39, 1430-1442.
34. Ferraro, L., Tanganelli, S., O'Connor, W.T., Bianchi, C., Ungerstedt, U. & Fuxe, K. (1995) Neurotensin increases endogenous glutamate release in the neostriatum of the awake rat. Synapse, 20, 362-364.
35. Ferraro, L., O'Connor, W.T., Antonelli, T., Fuxe, K. & Tanganelli, S. (1997) Differential effects of intrastriatal neurotensin(1-13) and neurotensin(8-13) on striatal dopamine and pallidal GABA release. A dual-probe microdialysis study in the awake rat. Eur. J. Neurosci., 9, 1838-1846.
36. Ferraro, L., Antonelli, T., O'Connor, W.T., Fuxe, K., Soubrié, P. & Tanganelli, S. (1998) The striatal neurotensin receptor modulates striatal and pallidal glutamate and GABA release: functional evidence for a pallidal glutamate-GABA interaction via the pallidal-subthalamic nucleus loop. J. Neurosci., 18, 6977-6989.
37. Ferraro, L., Tomasini, M.C., Fernandez, M., Bebe, B.W., O'Connor, W.T., Fuxe, K., Glennon, J.C., Tanganelli, S. & Antonelli, T. (2001) Nigral neurotensin receptor regulation of nigral glutamate and nigroventral thalamic GABA transmission: a dual-probe microdialysis study in intact conscious rat brain. Neuroscience, 102, 113-120.
38. Ferraro, L., Tomasini, M.C., Mazza, R., Fuxe, K., Fournier, J., Tanganelli, S. & Antonelli, T. (2008) Neurotensin receptors as modulators of glutamatergic transmission. Brain Res. Rev., 58, 365-373.
39. Ferraro, L., Tomasini, M.C., Beggiato, S., Guerrini, R., Salvadori, S., Fuxe, K., Calzà, L., Tanganelli, S. & Antonelli, T. (2009) Emerging evidence for neurotensin receptor 1 antagonists as novel pharmaceutics in neurodegenerative disorders. Mini Rev. Med. Chem., 9, 1429-1438.
40. Ferraro, L., Beggiato, S., Tomasini, M.C., Fuxe, K., Tanganelli, S. & Antonelli, T. (2011) Neurotensin regulates cortical glutamate transmission by modulating N-methyl-D-aspartate receptor functional activity: an in vivo microdialysis study. J. Neurosci. Res., 89, 1618-1626.
41. Ferré, S., O'Connor, W.T., Fuxe, K. & Ungerstedt, U. (1993) The striopallidal neuron: a main locus for adenosine-dopamine interactions in the brain. J. Neurosci., 13, 5402-5406.
42. Frankel, P.S., Hoonakker, A.J., Alburges, M.E., McDougall, J.W., McFadden, L.M., Fleckenstein, A.E. & Hanson, G.R. (2011) Effect of methamphetamine self-administration on neurotensin systems of the basal ganglia. J. Pharmacol. Exp. Ther., 336, 809-815.
43. Fuxe, K., Agnati, L.F., von Euler, G., Tanganelli, S., O'Connor, W.T., Ferré, S., Hedlund, P. & Zoli, M. (1992a) Neuropeptides, excitatory amino acid and adenosine A2 receptors regulate D2 receptors via intramembrane receptor-receptor interactions. Relevance for Parkinson's disease and schizophrenia. Neurochem. Int., 20, 215S-224S.
44. Fuxe, K., O'Connor, W.T., Antonelli, T., Osborne, P.G., Tanganelli, S., Agnati, L.F. & Ungerstedt, U. (1992b) Evidence for a substrate of neuronal plasticity based on pre-and postsynaptic neurotensin-dopamine receptor interactions in the neostriatum. Proc. Natl. Acad. Sci. USA, 89, 5591-5595.
45. Fuxe, K., Li, X.M., Tanganelli, S., Hedlund, P., O'Connor, W.T., Ferraro, L., Ungerstedt, U. & Agnati, L.F. (1995) Receptor-receptor interactions and their relevance for receptor diversity. Focus on neuropeptide/dopamine interactions. Ann. NY Acad. Sci., 757, 365-376.
46. Fuxe, K., Marcellino, D., Borroto-Escuela, D.O., Frankowska, M., Ferraro, L., Guidolin, D., Ciruela, F. & Agnati, L.F. (2010) The changing world of G protein-coupled receptors: from monomers to dimers and receptor mosaics with allosteric receptor-receptor interactions. J. Recept. Signal Transduct. Res., 30, 272-283.
47. Galeffi, F., Bianchi, L., Bolam, J.P. & Della Corte, L. (2003) The effect of 6-hydroxydopamine lesions on the release of amino acids in the direct and indirect pathways of the basal ganglia: a dual microdialysis probe analysis. Eur. J. Neurosci., 18, 856-868.
48. Ganguly, A. & Keefe, K.A. (2001) Unilateral dopamine depletion increases expression of the 2A subunit of the N-methyl-D-aspartate receptor in enkephalin-positive and enkephalin-negative neurons. Neuroscience, 103, 405-412.
49. Goulet, M., Morissette, M., Grondin, R., Falardeau, P., Bédard, P.J., Rostène, W. & Di Paolo, T. (1999) Neurotensin receptors and dopamine transporters: effects of MPTP lesioning and chronic dopaminergic treatments in monkeys. Synapse, 32, 153-164.
50. Gruber, S.H., Nomikos, G.G. & Mathé, A.A. (2002) d-Amphetamine-induced increase in neurotensin and neuropeptide Y outflow in the ventral striatum is mediated via stimulation of dopamine D1 and D2/3 receptors. J. Neurosci. Res., 69, 133-139.
51. Hanson, G.R. & Keefe, K.A. (1999) Dopamine D-1 regulation of caudate neurotensin mRNA in the presence or absence of the nigrostriatal dopamine pathway. Brain Res. Mol. Brain Res., 66, 111-121.
52. Herve, D., Tassin, J.P., Studler, J.M., Dana, C., Kitabgi, P., Vincent, J.P., Glowinski, J. & Rostene, W. (1986) Dopaminergic control of 125I-labeled neurotensin binding site density in corticolimbic structures of the rat brain. Proc. Natl. Acad. Sci. USA, 83, 6203-6207.
53. Jonkers, N., Sarre, S., Ebinger, G. & Michotte, Y. (2002) MK801 suppresses the L-DOPA-induced increase of glutamate in striatum of hemi-Parkinson rats. Brain Res., 926, 149-155.
54. Katsanos, G.S., Anogianaki, A., Castellani, M.L., Ciampoli, C., De Amicis, D., Orso, C., Pollice, R., Vecchiet, J., Tetè, S., Salini, V., Caraffa, A., Patruno, A., Shaik, Y.B., Kempuraj, D., Doyle, R., Antinolfi, P.L., Cerulli, G., Conti, C.M., Fulcheri, M., Neri, G. & Sabatino, G. (2008) Biology of neurotensin: revisited study. Int. J. Immunopathol. Pharmacol., 21, 255-259.
55. Kitabgi, P., Carraway, R. & Leeman, S.E. (1976) Isolation of a tridecapeptide from bovine intestinal tissue and its partial characterization as neurotensin. J. Biol. Chem., 251, 7053-7058.
56. Kuschinsky, K. & Hornykiewicz, O. (1972) Morphine catalepsy in the rat: relation to striatal dopamine metabolism. Eur. J. Pharmacol., 19, 119-122.
57. Liang, Y., Boules, M., Li, Z., Williams, K., Miura, T., Oliveros, A. & Richelson, E. (2010) Hyperactivity of the dopaminergic system in NTS1 and NTS2 null mice. Neuropharmacology, 58, 1199-1205.
58. Lutsenko, V.K., Vukolova, M.N., Kucheryanu, V.G. & Gudasheva, T.A. (2003) Dipeptide analog of neurotensin active site prevents the development of experimental Parkinson's syndrome in mice. Bull. Exp. Biol. Med., 136, 352-354.
59. Marti, M., Sbrenna, S., Fuxe, K., Bianchi, C., Beani, L. & Morari, M. (2000) Increased responsivity of glutamate release from the substantia nigra pars reticulata to striatal NMDA receptor blockade in a model of Parkinson's disease. A dual probe microdialysis study in hemiparkinsonian rats. Eur. J. Neurosci., 12, 1848-1850.
60. Marti, M., Mela, F., Bianchi, C., Beani, L. & Morari, M. (2002) Striatal dopamine-NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo: opposite role for D1 and D2 receptors. J. Neurochem., 83, 635-644.
61. Marti, M., Manzalini, M., Fantin, M., Bianchi, C., Della Corte, L. & Morari, M. (2005) Striatal glutamate release evoked in vivo by NMDA is dependent upon ongoing neuronal activity in the substantia nigra, endogenous striatal substance P and dopamine. J. Neurochem., 93, 195-205.
62. Merchant, K.M. & Miller, M.A. (1994) Coexpression of neurotensin and c-fos mRNAs in rat neostriatal neurons following acute haloperidol. Brain Res. Mol. Brain Res., 23, 271-277.
63. Meshul, C.K., Emre, N., Nakamura, C.M., Allen, C., Donohue, M.K. & Buckman, J.F. (1999) Time-dependent changes in striatal glutamate synapses following a 6-hydroxydopamine lesion. Neuroscience, 88, 1-16.
64. Morgese, M.G., Cassano, T., Gaetani, S., Macheda, T., Laconca, L., Dipasquale, P., Ferraro, L., Antonelli, T., Cuomo, V. & Giuffrida, A. (2009) Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55, 212-2. Neurochem. Int., 54, 56-64.
65. Nemeroff, C.B. & Cain, S.T. (1985) Neurotensin-dopamine interactions in the CNS. Trends Pharmacol. Sci., 6, 201-205.
66. Ochi, M., Koga, K., Kurokawa, M., Kase, H., Nakamura, J. & Kuwana, Y. (2000) Systemic administration of adenosine A(2A) receptor antagonist reverses increased GABA release in the globus pallidus of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study. Neuroscience, 100, 53-62.
67. Parent, A. & Hazrati, L.N. (1995) Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res. Brain Res. Rev., 20, 91-127.
68. Paxinos, G. & Watson, C. (1986) The Rat Brain in Stereotaxic Coordinates. Academic Press, New York.
69. Quirion, R., Chiueh, C.C., Everist, H.D. & Pert, A. (1985) Comparative localization of neurotensin receptors on nigrostriatal and mesolimbic dopaminergic terminals. Brain Res., 327, 385-389.
70. Radke, J.M., Owens, M.J. & Nemeroff, C.B. (2001) The effects of glutamate receptor agonists on neurotensin release using in vivo microdialysis. Eur. J. Pharmacol., 411, 129-134.
71. Rashid, A.J., So, C.H., Kong, M.M., Furtak, T., El-Ghundi, M., Cheng, R., O'Dowd, B.F. & George, S.R. (2007) D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum. Proc. Natl. Acad. Sci. USA, 104, 654-659.
72. Reid, M.S., O'Connor, W.T., Herrera-Marschitz, M. & Ungerstedt, U. (1990) The effects of intranigral GABA and dynorphin A injections on striatal dopamine and GABA release: evidence that dopamine provides inhibitory regulation of striatal GABA neurons via D2 receptors. Brain Res., 519, 255-260.
73. Robertson, G.S., Tetzlaff, W., Bedard, A., St.-Jean, M. & Wigle, N. (1995) c-fos mediates antipsychotic-induced neurotensin gene expression in the rodent striatum. Neuroscience, 67, 325-344.
74. 3H] 3-(2-Carboxypiperazin-4-yl) propyl-1-phosphoric acid binding. J. Neurochem., 54, 1926-1933.
75. Sanberg, P.R., Bunsey, M.D., Giordano, M. & Norman, A.B. (1988) The catalepsy test: its ups and downs. Behav. Neurosci., 102, 748-759.
76. Schwarting, R.K. & Huston, J.P. (1996) The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog. Neurobiol., 50, 275-331.
77. See, R.E., Berglind, W.J., Krentz, L. & Meshul, C.K. (2002) Convergent evidence from microdialysis and presynaptic immunolabeling for the regulation of gamma-aminobutyric acid release in the globus pallidus following acute clozapine or haloperidol administration in rats. J. Neurochem., 82, 172-180.
78. Sirinathsinghji, D.J. & Heavens, R.P. (1989) Stimulation of GABA release from the rat neostriatum and globus pallidus in vivo by corticotropin-releasing factor. Neurosci. Lett., 22, 203-209.
79. St-Gelais, F., Jomphe, C. & Trudeau, L.E. (2006) The role of neurotensin in central nervous system pathophysiology: what is the evidence? J. Psychiatry Neurosci., 31, 229-245.
80. Szigethy, E. & Beaudet, A. (1989) Correspondence between high affinity 125I-neurotensin binding sites and dopaminergic neurons in the rat substantia nigra and ventral tegmental area: a combined radioautographic and immunohistochemical light microscopic study. J. Comp. Neurol., 279, 128-137.
81. Tanganelli, S., von Euler, G., Fuxe, K., Agnati, L.F. & Ungerstedt, U. (1989) Neurotensin counteracts apomorphine-induced inhibition of dopamine release as studied by microdialysis in rat neostriatum. Brain Res., 502, 319-324.
82. Tanganelli, S., O'Connor, W.T., Ferraro, L., Bianchi, C., Beani, L., Ungerstedt, U. & Fuxe, K. (1994) Facilitation of GABA release by neurotensin is associated with a reduction of dopamine release in rat nucleus accumbens. Neuroscience, 60, 649-657.
83. Tanji, H., Araki, T., Fujihara, K., Nagasawa, H. & Itoyama, Y. (1999) Alteration of neurotensin receptors in MPTP-treated mice. Peptides, 20, 803-807.
84. Taylor, M.D., De Ceballos, M.L., Rose, S., Jenner, P. & Marsden, C.D. (1992) Effects of a unilateral 6-hydroxydopamine lesion and prolonged L-3, 4-dihydroxyphenylalanine treatment on peptidergic systems in rat basal ganglia. Eur. J. Pharmacol., 219, 183-192.
85. Tossman, U., Segovia, J. & Ungerstedt, U. (1986) Extracellular levels of amino acids in striatum and globus pallidus of 6-hydroxydopamine-lesioned rats measured with microdialysis. Acta Physiol. Scand., 127, 547-551.
86. Tremblay, M., Salin, P. & Soghomonian, J.J. (1995) Effect of 6-OHDA lesions on striatal mRNA levels encoding for glutamate receptor subunits. Neuroreport, 6, 2225-2229.
87. Ulas, J., Weihmuller, F.B., Brunner, L.C., Joyce, J.N., Marshall, J.F. & Cotman, C.W. (1994) Selective increase of NMDA-sensitive glutamate binding in the striatum of Parkinson's disease, Alzheimer's disease, and mixed Parkinson's disease/Alzheimer's disease patients: an autoradiographic study. J. Neurosci., 14, 6317-6324.
88. Ungerstedt, U. & Arbuthnott, G.W. (1970) Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res., 18, 485-493.
89. Vincent, J.P., Mazella, J. & Kitabgi, P. (1999) Neurotensin and neurotensin receptors. Trends Pharmacol. Sci., 20, 302-309.
90. Wagstaff, J.D., Gibb, J.W. & Hanson, G.R. (1996) Dopamine D2-receptors regulate neurotensin release from nucleus accumbens and striatum as measured by in vivo microdialysis. Brain Res., 721, 196-203.
91. Wang, S., Hu, L.F., Zhang, Y., Sun, T., Sun, Y.H., Liu, S.Y., Ding, J.H., Wu, J. & Hu, G. (2006) Effects of systemic administration of iptakalim on extracellular neurotransmitter levels in the striatum of unilateral 6-hydroxydopamine-lesioned rats. Neuropsychopharmacology, 31, 933-940.
92. Wullner, U., Testa, C.M., Catania, M.V., Young, A.B. & Penney, J.B. (1994) Glutamate receptors in striatum and substantia nigra: effects of medial forebrain bundle lesions. Brain Res., 645, 98-102.
93. Xue, Y., Bai, B., Yung, W.H. & Chen, L. (2009) Electrophysiological effects of neurotensin on globus pallidus neurons of 6-hydroxydopamine-lesioned rats. Neurosignals, 17, 153-161.
94. Zahm, D.S. & Johnson, S.N. (1989) Asymmetrical distribution of neurotensin immunoreactivity following unilateral injection of 6-hydroxydopamine in rat ventral tegmental area (VTA). Brain Res., 483, 301-311.
95. Zhou, M., Peterson, C.L., Lu, Y.B. & Nadler, J.V. (1995) Release of glutamate and aspartate from CA1 synaptosomes: selective modulation of aspartate release by ionotropic glutamate receptor ligands. J. Neurochem., 64, 1556-1566.